These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19344670)

  • 1. Migraine prophylaxis with botulinum toxin A is associated with perception of headache.
    Burstein R; Dodick D; Silberstein S
    Toxicon; 2009 Oct; 54(5):624-7. PubMed ID: 19344670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.
    Jakubowski M; McAllister PJ; Bajwa ZH; Ward TN; Smith P; Burstein R
    Pain; 2006 Dec; 125(3):286-295. PubMed ID: 17069972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imploding and exploding migraine headaches: comparison of methods to diagnose pain directionality.
    Files JA; Schwedt TJ; Mayer AP; David PS; Vargas BB; Chang YH; Hunt M; Patel S; Ko MG; Tozer BS; Burstein R; Dodick DW
    Headache; 2014 Jun; 54(6):1010-8. PubMed ID: 24527766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.
    Fernández-de-Las-Peñas C; Arendt-Nielsen L; Simons DG
    Pain; 2007 Jun; 129(3):363-364. PubMed ID: 17360120
    [No Abstract]   [Full Text] [Related]  

  • 5. Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B.
    Grogan PM; Alvarez MV; Jones L
    Headache; 2013 Jan; 53(1):126-136. PubMed ID: 23126597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting migraine responsiveness to botulinum toxin type A injections.
    Kim CC; Bogart MM; Wee SA; Burstein R; Arndt KA; Dover JS
    Arch Dermatol; 2010 Feb; 146(2):159-63. PubMed ID: 20157026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxins for the prevention of migraine in adults.
    Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
    Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
    Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
    Binder WJ; Brin MF; Blitzer A; Schoenrock LD; Pogoda JM
    Otolaryngol Head Neck Surg; 2000 Dec; 123(6):669-76. PubMed ID: 11112955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
    Jackson JL; Kuriyama A; Hayashino Y
    JAMA; 2012 Apr; 307(16):1736-45. PubMed ID: 22535858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A
    Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP; Schaecher K; Cannon HE; Speckman M
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
    Bruloy E; Sinna R; Grolleau JL; Bout-Roumazeilles A; Berard E; Chaput B
    Plast Reconstr Surg; 2019 Jan; 143(1):239-250. PubMed ID: 30589800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A in refractory chronic migraine: an open-label trial.
    Menezes C; Rodrigues B; Magalhães E; Melo A
    Arq Neuropsiquiatr; 2007 Sep; 65(3A):596-8. PubMed ID: 17876397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A for the treatment of migraine.
    Aurora S
    Expert Opin Pharmacother; 2006 Jun; 7(8):1085-95. PubMed ID: 16722818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.